The PharmaFlow platform, preserving both the whole BM or whole PB environment and the real Effector to Target (E:T) ratios, measures the killing activity of these activated T cells against tumor cells by an effective E:T ratio defined as how many tumor cells are killed by every activated T cell (CD4+ or CD8+, and CD25+). In addition, we can also measure other key parameters to predict the in vitro response after bispecific antibodies (or similar formats) exposure, such as the basal E:T ratio, tumor antigen expression (ie, CD123, BCMA, CD19…), T-cell expansion or expression of immune checkpoints on target and effector cells before and after the cell culture. The integration of all these rational parameters, together with the pharmacological data (EC50, Emax, AUC), allow us to generate a predictive model of in vitro response and select those samples with higher T-cell cytotoxicity or patients with a remarkable immune resistance. The PharmaFlow platform represents a nice approach to evaluate multiple checkpoint molecules or combinatorial drug treatments that could enhance the bispecific antibody cytotoxicity reverting to the leukemic cells to escape from cytokine-mediated immune responses.